



## **Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference**

**CAMBRIDGE, MA, August 8, 2018** – [Catabasis Pharmaceuticals, Inc.](http://www.catabasis.com) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference on Wednesday, August 15, 2018 at 2:30pm ET at the Le Parker Meridien Hotel in New York, NY.

A webcast of the presentation will be available in the Investors section of the Company's website, [www.catabasis.com](http://www.catabasis.com), and will be archived for 30 days following the presentation.

### **About Catabasis**

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF- $\kappa$ B inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 POLARIS DMD trial is expected to initiate in the second half of 2018. For more information on edasalonexent and our Phase 3 POLARIS DMD trial, please visit [www.catabasis.com](http://www.catabasis.com).

###

### Investor and Media Contact

Andrea Matthews

Catabasis Pharmaceuticals, Inc.

T: (617) 349-1971

[amatthews@catabasis.com](mailto:amatthews@catabasis.com)